Immunogenicity to infliximab is associated with HLA-DRB1

Gut

Volumn 64, Issue 8, 2015, Pages 1344-1345

  Billiet, Thomas ^a   Vande Casteele, Niels ^b   Van Stappen, Thomas ^b   Princen, Fred ^c   Singh, Sharat ^c   Gils, Ann ^b   Ferrante, Marc ^d   Van Assche, Gert ^d   Cleynen, Isabelle ^d   Vermeire, Severine ^d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c Prometheus Laboratories   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DRUG ANTIBODY; GLUTAMIC ACID; HLA DRB1 ANTIGEN; INFLIXIMAB; INFLIXIMAB ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; CONTROLLED STUDY; CROHN DISEASE; GENE FREQUENCY; HUMAN; IMMUNOGENICITY; LETTER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; BLOOD; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; MALE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MALE;

EID: 84940459362     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309698     Document Type: Letter

References (4)

1. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014;63:1258-64.
2. Buck D, Cepok S, Hoffmann S, et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011;68:480-7.
3. Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1∗01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 2015;47:172-9.
4. Ranasinghe S, Cutler S, Davis I, et al. Association of HLA-DRB1-restricted CD4(+) T cell responses with HIV immune control. Nat Med 2013;19:930-3.